Thank you @endpts.com for sharing the story about Grace Science, so close to bringing gene therapy to patients with NGly1 disease, hoping for some regulatory flexibility.
endpoints.news/grace-scienc...
Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September without new funding or a regulatory break.
